TIDMPRTC
RNS Number : 6033C
PureTech Health PLC
13 June 2023
13 June 2023
PureTech Health plc
Results of Annual General Meeting
The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC,
LSE: PRTC) ("PureTech Health" or the "Company") was held at 11 a.m.
EDT/4 p.m. BST on Tuesday, June 13, 2023.
All of the resolutions proposed at the Annual General Meeting
were duly passed by the shareholders on a poll.
The results of the poll, incorporating the proxy votes lodged in
advance of the meeting, are set out below. All resolutions were
passed by greater than 93% of the shares voted at the meeting.
Resolutions For % Against % Withheld Total
votes
cast
001. To approve
the Company's
Annual Report
and Accounts for
year ended 31
December 2022 218,239,144 100.00% 0 0.00% 1,856 218,239,144
------------ -------- ----------- ------ --------- ------------
002. To approve
the Directors'
Remuneration Report 208,436,087 95.51% 9,804,137 4.49% 776 218,240,224
------------ -------- ----------- ------ --------- ------------
003. To elect
Ms. Sharon Barber-Lui
as a director 217,708,896 99.76% 530,758 0.24% 1,346 218,239,654
------------ -------- ----------- ------ --------- ------------
004. To elect
Dr. Raju Kucherlapati
as a director 217,673,486 99.74% 564,168 0.26% 3,346 218,237,654
------------ -------- ----------- ------ --------- ------------
005. To elect
Dr. John LaMattina
as a director 208,905,865 95.72% 9,331,788 4.28% 3,347 218,237,653
------------ -------- ----------- ------ --------- ------------
006. To elect
Ms. Kiran Mazumdar-Shaw
as a director 204,963,784 93.92% 13,275,369 6.08% 1,847 218,239,153
------------ -------- ----------- ------ --------- ------------
007. To elect
Dr. Robert Langer
as a director 213,495,366 97.83% 4,743,812 2.17% 1,822 218,239,178
------------ -------- ----------- ------ --------- ------------
008. To elect
Ms. Daphne Zohar
as a director 218,236,986 100.00% 2,693 0.00% 1,321 218,239,679
------------ -------- ----------- ------ --------- ------------
009. To elect
Dr. Bharatt Chowrira
as a director 217,679,376 99.99% 30,161 0.01% 531,463 217,709,537
------------ -------- ----------- ------ --------- ------------
010. To appoint
PricewaterhouseCoopers
LLP as the auditors
of the Company 217,704,419 99.75% 535,776 0.25% 805 218,240,195
------------ -------- ----------- ------ --------- ------------
011. To authorize
the Audit Committee
to determine the
Auditors' remuneration 218,232,344 100.00% 6,151 0.00% 2,505 218,238,495
------------ -------- ----------- ------ --------- ------------
012. To authorize
the allotment
of shares 218,208,524 99.99% 31,471 0.01% 1,005 218,239,995
------------ -------- ----------- ------ --------- ------------
013. To approve
the Company's
new Performance
Share Plan 211,285,130 96.81% 6,952,233 3.19% 3,637 218,237,363
------------ -------- ----------- ------ --------- ------------
014. To disapply
pre-emption rights 217,137,254 99.50% 1,101,010 0.50% 2,736 218,238,264
------------ -------- ----------- ------ --------- ------------
015. To further
disapply pre-emption
rights as if section
561 of the Companies
Act 2006 did not
apply to any allotment
of equity securities
for cash or sale
of treasury shares
for cash 214,933,920 98.49% 3,304,344 1.51% 2,736 218,238,264
------------ -------- ----------- ------ --------- ------------
016. To authorize
market purchase
of own shares 217,711,818 99.76% 528,167 0.24% 1,015 218,239,985
------------ -------- ----------- ------ --------- ------------
017. To authorize
general meetings
to be called on
not less than
14 clear days'
notice 217,917,408 99.85% 322,238 0.15% 1,354 218,239,646
------------ -------- ----------- ------ --------- ------------
Notes:
(1) A vote "Withheld" is not a vote in law and is not counted in
the calculation of the votes "For" or "Against" a resolution.
(2) As at June 9, 2023, the record date for the Annual General
Meeting, the number of issued shares in the Company entitling the
holders to attend and vote for or against all the resolutions at
the AGM was 277,430,684 ordinary shares. This does not include
12,037,475 shares held in treasury by the Company. In accordance
with the Company's Articles of Association, on a poll every member
present in person or by proxy has one vote for every share
held.
(3) The full text of the resolutions may be found in the Notice
of the Annual General Meeting, copies of which are available on
both the Company's website
https://investors.puretechhealth.com/financials-filings/reports and
on the National Storage Mechanism.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to giving life to new classes of medicine to change the lives of
patients with devastating diseases. The Company has created a broad
and deep pipeline through its experienced research and development
team and its extensive network of scientists, clinicians and
industry leaders that is being advanced both internally and through
its Founded Entities. PureTech's R&D engine has resulted in the
development of 27 therapeutics and therapeutic candidates,
including two (Plenity(R) and EndeavorRx(R)) that have received
both US FDA clearance and European marketing authorization and a
third (KarXT) that is expected to be filed soon for FDA approval. A
number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical
development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation
points.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those related to our future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks, uncertainties and other important factors that could cause
actual results, performance and achievements to differ materially
from current expectations, including, but not limited to, those
risks, uncertainties and other important factors described under
the caption "Risk Factors" in our Annual Report on Form 20-F for
the year ended December 31, 202 2 filed with the SEC and in our
other regulatory filings. These forward-looking statements are
based on assumptions regarding the present and future business
strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only
as at the date of this press release. Except as required by law and
regulatory requirements, we disclaim any obligation to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGNKNBKABKDAAD
(END) Dow Jones Newswires
June 13, 2023 12:07 ET (16:07 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024